QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)

Vaccine Stocks List

Compare vaccine stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Learn more about trading vaccine stocks.

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$78.21
-0.8%
$81.15
$57.17
$89.74
$97.56 B0.385.85 million shs5.05 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$125.33
-0.2%
$143.39
$115.03
$217.25
$47.78 B1.73.55 million shs2.99 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$7.42
-4.3%
$7.56
$5.61
$76.77
$668.86 M1.726.42 million shs4.57 million shs
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$158.48
-0.3%
$159.41
$150.11
$183.35
$411.85 B0.537.74 million shs5.17 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$36.48
-0.7%
$39.79
$36.17
$54.93
$205.94 B0.6322.55 million shs27.27 million shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
+0.63%+0.90%-5.76%-5.49%+24.74%
Moderna, Inc. stock logo
MRNA
Moderna
+0.37%-4.02%-12.78%-27.13%-11.74%
Novavax, Inc. stock logo
NVAX
Novavax
+1.44%-13.79%-18.08%-22.42%-85.08%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-0.22%-1.65%-4.03%+0.47%-11.09%
Pfizer Inc. stock logo
PFE
Pfizer
-0.70%-4.05%-10.76%-14.44%-28.42%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
3.0957 of 5 stars
2.33.04.24.12.82.53.8
Moderna, Inc. stock logo
MRNA
Moderna
2.6877 of 5 stars
4.21.00.04.62.93.31.3
Novavax, Inc. stock logo
NVAX
Novavax
2.1912 of 5 stars
3.02.00.04.72.42.50.6
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.8429 of 5 stars
2.25.03.33.93.32.51.9
Pfizer Inc. stock logo
PFE
Pfizer
3.4297 of 5 stars
4.23.05.04.62.23.31.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
2.53
Moderate Buy$91.0017.01% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.36
Hold$179.1345.04% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.00
Hold$65.57778.97% Upside
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.46
Hold$173.009.36% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.31
Hold$47.3330.29% Upside

Current Analyst Ratings

Latest Vaccine Stocks Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/17/2023
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
5/16/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$90.00 ➝ $100.00
5/11/2023
Pfizer Inc. stock logo
PFE
Pfizer
Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Neutral$38.00
5/10/2023
Novavax, Inc. stock logo
NVAX
Novavax
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$110.00 ➝ $35.00
5/5/2023
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$185.00 ➝ $153.00
5/5/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$168.00 ➝ $170.00
5/5/2023
Pfizer Inc. stock logo
PFE
Pfizer
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$41.00 ➝ $39.00
5/3/2023
Pfizer Inc. stock logo
PFE
Pfizer
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$43.00 ➝ $40.00
4/25/2023
Moderna, Inc. stock logo
MRNA
Moderna
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral
4/21/2023
Pfizer Inc. stock logo
PFE
Pfizer
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral$50.00 ➝ $45.00
4/20/2023
Novavax, Inc. stock logo
NVAX
Novavax
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
(Data available from 5/18/2020 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$27.28B3.56$8.92 per share8.72$16.79 per share4.63
Moderna, Inc. stock logo
MRNA
Moderna
$19.26B2.44$22.46 per share5.50$49.48 per share2.50
Novavax, Inc. stock logo
NVAX
Novavax
$1.98B0.32N/AN/A($10.38) per share-0.72
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.94B4.33$12.91 per share12.25$27.27 per share5.80
Pfizer Inc. stock logo
PFE
Pfizer
$92.95B2.21$7.48 per share4.86$17.93 per share2.03

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$4.59B$4.4317.5610.710.9020.65%39.35%13.11%8/1/2023 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
$8.36B$11.5710.68N/AN/A31.77%25.87%18.75%8/2/2023 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$657.94M-$14.37N/AN/AN/A-85.02%N/A-53.17%8/14/2023 (Estimated)
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$17.94B$4.7833.0914.372.7213.22%36.13%14.66%7/18/2023 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$31.37B$5.087.1510.691.2331.25%37.53%18.08%7/27/2023 (Estimated)

Latest Vaccine Stocks Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2023Q1 23
Novavax, Inc. stock logo
NVAX
Novavax
-$3.38-$3.41-$0.03-$3.41$94.52 million$81.00 million      
5/4/2023Q1 2023
Moderna, Inc. stock logo
MRNA
Moderna
-$1.77$0.19+$1.96$0.19$1.17 billion$1.86 billion    
5/2/2023Q1 2023
Pfizer Inc. stock logo
PFE
Pfizer
$1.00$1.23+$0.23$1.49$16.49 billion$18.28 billion    
4/27/2023Q1 2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$1.63$1.37-$0.26$1.94$6.33 billion$6.35 billion    
4/18/2023Q1 23
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.51$2.68+$0.17$5.39$23.61 billion$24.75 billion    
2/28/2023Q4 22
Novavax, Inc. stock logo
NVAX
Novavax
-$0.92-$2.28-$1.36-$2.28$383.14 million$357.40 million    
2/23/2023Q4 2022
Moderna, Inc. stock logo
MRNA
Moderna
$4.66$3.61-$1.05$3.61$5.02 billion$5.08 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
$3.003.86%+5.03%67.72%8 Years
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$4.522.86%+5.87%94.56%62 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.644.51%+3.31%32.28%12 Years

Latest Vaccine Stocks Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2023
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
Quarterly$0.753.65%6/14/20236/15/20236/29/2023
4/26/2023
Pfizer Inc. stock logo
PFE
Pfizer
quarterly$0.414.25%5/11/20235/12/20236/9/2023
4/18/2023
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Quarterly$1.192.96%5/22/20235/23/20236/6/2023
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
1.10
1.28
1.13
Moderna, Inc. stock logo
MRNA
Moderna
0.04
3.46
3.26
Novavax, Inc. stock logo
NVAX
Novavax
N/A
0.51
0.49
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.49
1.07
0.85
Pfizer Inc. stock logo
PFE
Pfizer
0.31
1.37
1.11

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
78.72%
Moderna, Inc. stock logo
MRNA
Moderna
63.11%
Novavax, Inc. stock logo
NVAX
Novavax
45.70%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
67.94%
Pfizer Inc. stock logo
PFE
Pfizer
67.62%

Insider Ownership

CompanyInsider Ownership
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
0.21%
Moderna, Inc. stock logo
MRNA
Moderna
15.70%
Novavax, Inc. stock logo
NVAX
Novavax
1.40%
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.20%
Pfizer Inc. stock logo
PFE
Pfizer
0.05%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
17,0001.25 billion1.24 billionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900381.21 million321.36 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,99286.31 million85.10 millionOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
155,8002.60 billion2.59 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
83,0005.65 billion5.64 billionOptionable

Vaccine Stocks Headlines

SourceHeadline
US FDA panel backs Pfizers maternal RSV vaccine for protecting infantsUS FDA panel backs Pfizer's maternal RSV vaccine for protecting infants
msn.com - May 18 at 7:10 PM
Pfizer Named Top Dividend Stock With Insider Buying And 4.46% YieldPfizer Named Top Dividend Stock With Insider Buying And 4.46% Yield
forbes.com - May 18 at 7:10 PM
Pfizer: Ridiculous Selloff To A 2-Year LowPfizer: Ridiculous Selloff To A 2-Year Low
seekingalpha.com - May 18 at 7:10 PM
U.S. FDA panel backs Pfizers RSV vaccine for protecting infantsU.S. FDA panel backs Pfizer's RSV vaccine for protecting infants
finance.yahoo.com - May 18 at 7:10 PM
FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal ImmunizationFDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
finance.yahoo.com - May 18 at 7:10 PM
FDA panel votes on Pfizer RSV vaccine following efficacy dataFDA panel votes on Pfizer RSV vaccine following efficacy data
finance.yahoo.com - May 18 at 7:10 PM
RSV vaccine for pregnant women protects their newborns but is it ready for US sale?RSV vaccine for pregnant women protects their newborns but is it ready for US sale?
finance.yahoo.com - May 18 at 2:10 PM
UPDATE 1-US FDA advisers discuss Pfizers maternal RSV vaccineUPDATE 1-US FDA advisers discuss Pfizer's maternal RSV vaccine
finance.yahoo.com - May 18 at 2:10 PM
US FDA advisers to discuss Pfizers maternal RSV vaccineUS FDA advisers to discuss Pfizer's maternal RSV vaccine
msn.com - May 18 at 9:09 AM
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (PFE)Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (PFE)
marketbeat.com - May 18 at 7:08 AM
Pfizer: A Lackluster Valuation And Soft Growth Outlook Despite Strong Free Cash FlowPfizer: A Lackluster Valuation And Soft Growth Outlook Despite Strong Free Cash Flow
seekingalpha.com - May 17 at 11:59 PM
M&A crackdown a ‘disaster’ for pharma sector, Pfizer executive warnsM&A crackdown a ‘disaster’ for pharma sector, Pfizer executive warns
finance.yahoo.com - May 17 at 7:40 PM
Pfizers Bond Sale Ranks Among Largest EverPfizer's Bond Sale Ranks Among Largest Ever
finance.yahoo.com - May 17 at 7:40 PM
Cantor Fitzgerald Reiterates Pfizer (PFE) Overweight RecommendationCantor Fitzgerald Reiterates Pfizer (PFE) Overweight Recommendation
msn.com - May 17 at 2:39 PM
Pfizer Unusual Options Activity For May 17Pfizer Unusual Options Activity For May 17
msn.com - May 17 at 2:39 PM
Pfizer Inc DRC (PFE)Pfizer Inc DRC (PFE)
uk.investing.com - May 17 at 9:39 AM
Startup Gradiant Reaches Billion-Dollar Valuation Cleaning Up Wastewater For TSMC, Coca-Cola And PfizerStartup Gradiant Reaches Billion-Dollar Valuation Cleaning Up Wastewater For TSMC, Coca-Cola And Pfizer
forbes.com - May 17 at 9:39 AM
FDA Signals Support For Pfizers Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen DealFDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
msn.com - May 17 at 9:39 AM
Pfizer prices an eight series $31B debt offering to fund the acquisition of SeagenPfizer prices an eight series $31B debt offering to fund the acquisition of Seagen
msn.com - May 17 at 9:39 AM
Q2 2023 EPS Estimates for Pfizer Inc. (NYSE:PFE) Reduced by Zacks ResearchQ2 2023 EPS Estimates for Pfizer Inc. (NYSE:PFE) Reduced by Zacks Research
marketbeat.com - May 17 at 6:31 AM
Pfizer Inc. (NYSE:PFE) Receives $47.33 Consensus Target Price from BrokeragesPfizer Inc. (NYSE:PFE) Receives $47.33 Consensus Target Price from Brokerages
americanbankingnews.com - May 17 at 2:58 AM
Pfizer plans to raise $31 billion from debt offering to finance Seagen takeoverPfizer plans to raise $31 billion from debt offering to finance Seagen takeover
investing.com - May 16 at 8:20 PM
Pfizer Prices $31,000,000,000 Debt OfferingPfizer Prices $31,000,000,000 Debt Offering
finance.yahoo.com - May 16 at 8:20 PM
Pfizer plans $31 billion debt offering to fund Seagen takeoverPfizer plans $31 billion debt offering to fund Seagen takeover
ca.finance.yahoo.com - May 16 at 8:20 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Gilead Sciences logo

Gilead Sciences

NASDAQ:GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Moderna logo

Moderna

NASDAQ:MRNA
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Novavax logo

Novavax

NASDAQ:NVAX
Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
Johnson & Johnson logo

Johnson & Johnson

NYSE:JNJ
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women's Health and Wound Care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The MedTech segment offers products used in the interventional solutions. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Points

  • A high demand for vaccines and a growing global economy is increasing international demand for vaccines. 
  • The vaccine industry is rife with risks, including the risk of failed clinical trials and regulatory risks. 
  • Learn more about multiple methods to invest in medical developments and what might have been the best stocks to buy during coronavirus. 

While you may not be able to invest in a specific vaccine, there are plenty of ways for investors to put money into companies that research and manufacture vaccines. Vaccine stocks have spiked in popularity among investors following the onset of the COVID-19 pandemic. Many pharmaceutical and biotech companies are involved in vaccine development; some are publicly traded on stock exchanges. By investing in these companies, you can benefit from their success in developing and selling vaccines.

Ready to learn more about pharmaceutical and COVID vaccine stocks? Read on to learn more about multiple methods to invest in medical developments and what might have been the best stocks to buy during coronavirus

Overview of Vaccine Stocks

A vaccine stock is associated with a company that produces vaccines, researches new vaccine technologies and provides vaccine transportation services. Vaccine development typically involves extensive research and clinical trials, which federal governments may fund partially. 

Once regulatory agencies have approved a vaccine, it can be marketed and sold to healthcare providers and patients. Exploring a healthcare stock list will expose you to some of the largest players in the vaccine industry. 

Why Invest in Vaccine Stocks?

Vaccines are crucial tools used to treat and prevent hundreds of fatal illnesses and conditions. Investing in a pharmaceutical or biotech company involved in drug and gene therapy development can produce strong returns if the company passes successful trials. 

The demand for vaccines will continue to grow in the coming years as the global population continues to age. It can provide long-term growth potential for vaccine stocks, many of which also invest heavily in other sectors of the healthcare sphere. It may also offer diversification for your portfolio within the healthcare industry. 

how to invest in vaccine stocks

3 Ways to Invest in Vaccines 

While you can no longer invest in a COVID-19 stock before the vaccination's development, many other healthcare-centered stocks focus on vaccine development. 

Pharmaceutical Stocks

The easiest way to invest in companies researching vaccines is to invest in one of the many pharmaceutical companies devoting a portion of research and development funds to new vaccines. Large pharmaceutical companies such as Pfizer Inc. (NYSE: PFE) and Johnson & Johnson (NYSE: JNJ) have been developing vaccines for decades. 

JNJMajor pharmaceutical providers like Johnson & Johnson have rebounded since the onset of the COVID-19 pandemic. 

Major pharmaceutical providers have extensive research and development budgets, allowing them to simultaneously work on vaccines for various incurable illnesses. Major pharmaceutical companies may also invest heavily in clinical trials, regulatory compliance, and marketing efforts to get their products approved and reach patients needing them. 

Pharmaceutical companies may partner with the federal government to streamline or improve vaccine development. For example, the United States spent more than $18 billion on COVID-19 vaccine research and development. You can find a list of the best pharmaceutical stocks on MarketBeat

Biotech Companies

Biotech companies use advanced biotechnology techniques to create vaccines, which can involve genetically engineering viruses or bacteria. They may invest in research and development like pharmaceutical companies but devote most research to novel medical solutions using human genomes. Major companies in the biotech sphere include Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX)

Biotech stocks became popular among stock traders looking to invest in a COVID vaccine, as the virus seems unresponsive to known vaccine creation methods. For example, Moderna shot to the top of the list of best stocks to buy during the coronavirus, thanks to its breakthrough COVID-19 vaccine. Moderna's vaccine is based on mRNA (messenger RNA) technology, which introduces a small piece of genetic material called mRNA into the body. This advancement could not have been possible without biotech companies' capacity to isolate RNA from a sample of human DNA. 

While the cure for COVID-19 is no longer biotech companies' primary area of research, many continue to explore gene therapies to develop new treatment strategies. Future research areas in the biotech sphere include developing gene therapies for neurological disorders and gene editing projects. You can learn more about how to invest in biotech stocks and possibly COVID stocks. 

Vaccine Supply Chain Companies

Vaccinations often use living compounds or severely weakened forms of diseases to create vaccines. This creates a supply chain problem regarding product distribution, as vaccines usually need to be kept in a controlled environment, including at a specific temperature during transportation. 

Vaccine supplies specialize in transporting and storing temperature-sensitive products, including vaccines. These companies use specialized refrigerated trucks, containers and warehouses to ensure that vaccines stay at the proper temperature during transportation and storage. While they may not seem as important as pharmaceutical and biotech companies, vaccine supply chain providers play a crucial role in the healthcare system. Examples of vaccine supply chain companies include AmerisourceBergen Corp. (NYSE: ABC) and Cryoport Inc. (NASDAQ: CYRX).

How to Invest in Vaccine Stocks

If you've invested in the stock market before, you'll find that buying and selling vaccine stock is the same as buying any other type of tradable asset. If you're unfamiliar with investing, take the following steps to start your foray into the healthcare system and vaccines stock. 

Step 1: Explore healthcare stocks.

As we mentioned above, multiple types of companies are involved in manufacturing and distributing vaccines. Start by exploring healthcare stocks in the industry, and research each company's recent profit statements and analyst ratings to create a list of viable stock investments. To begin your search, you can explore some of the top medical stocks on MarketBeat

Another way to invest in the vaccine industry is to invest in exchange-traded funds (ETFs) or mutual funds focusing on the healthcare sector. These funds typically invest in a diversified portfolio of companies in the healthcare industry, including vaccine manufacturers. This approach can offer investors greater diversification and lower risk than investing in individual stocks. Research multiple investment vehicles and decide how you want to invest before proceeding. 

Step 2: Fund your brokerage account.

Before investing in assets from your healthcare stocks list, you must open a brokerage account. A brokerage account is a type of investment account that you can use to buy and sell shares of stocks by placing instructions with your broker. 

Research different brokerage firms to find the one that suits your investment goals and preferences. Consider factors such as fees, minimum balance requirements, investment options and customer service when selecting an account. Once you find a broker that suits your needs, apply for an account using your personal information. 

After submitting your application, the brokerage firm will typically verify your information and may require additional documentation. Once your account is approved, you can fund it by transferring money from your bank account. Some brokers may also allow you to invest in stocks using a credit or debit card. 

Step 3: Buy the stock and manage your investment.

Once you fund your account, you can start investing by buying and selling stocks, ETFs and other assets your broker offers. Select the asset that you're interested in purchasing, and place an order through your brokerage account. Most brokers offer various order types, allowing you to control the price you pay per share and when your order executes.

If your broker can complete the order according to your instructions, you'll see your shares in your brokerage account. Monitor your assets' performance and how they change in value to manage your investment. 

Pros and Cons of Investing in Vaccine Stocks

Like any investment, before investing in vaccine stocks, there are potential benefits and risks. 

Pros

The benefits of investing in vaccine stocks include:

  • High demand: Vaccines are in high demand globally, and the vaccine market should grow in the coming years. Vaccine stocks may be a good investment opportunity for those seeking long-term growth potential.
  • Positive growth prospects: Many vaccine manufacturers have seen significant growth in their stock prices over the past year after being classified as COVID-19 stocks. For example, Moderna's stock price spiked more than 200% during the height of the COVID-19 pandemic. Investing in vaccine stocks now can result in a significant profit if the company makes a successful vaccination debut. 
  • Potential for government support: Governments worldwide invest heavily in vaccine development and distribution. This funding can boost vaccine manufacturers' bottom lines, making them more attractive to investors.

Cons

On the flip side, the cons include:

  • Regulatory risk: Vaccine development and manufacturing are subject to stringent regulations from government agencies, which can lead to delays and increased costs. Regulatory risks can also increase if there are concerns about the safety or efficacy of vaccines produced by the company you invest in.
  • Possibility of failure in clinical trials: Vaccine development involves extensive clinical trials that can take several years to complete. These trials are costly and can fail to achieve their objective. This may lead to financial losses for investors.

Future of Vaccine Investing 

The COVID-19 pandemic has highlighted the importance of vaccine development and distribution. The demand for COVID-19 vaccines is likely to continue for the foreseeable future, and there may be additional opportunities for vaccine manufacturers to develop booster shots or new vaccine variants. Technological advancements uncovered during the investigation of COVID-19, such as the use of mRNA in vaccine development, may lead to breakthroughs that can benefit investors. 

Demand for vaccines should increase in the future due to increased globalization. The international demand for vaccines may create additional supply chain issues, especially when transporting vaccines across borders. Investors interested in diversifying their portfolio may want to explore international pharmaceutical stocks or supply chain management companies for future investment potential. 

Investing in Vaccine Stocks

While the vaccine industry provides plenty of opportunities for investors, its also a highly competitive and often risky sector for investors. A vaccine can only be distributed once proven safe and effective in a series of government-overseen trials. This can delay investor returns or even lead to losses if trials are unsuccessful. Be sure to explore all of the best biotech stocks on MarketBeat and the largest pharmaceutical companies in the world before choosing where to place your funds. 

FAQs

Look at some frequently asked questions before you get started on your own vaccine investing journey.

What companies make the COVID vaccine?

Several companies have developed COVID-19 vaccines, including Pfizer-BioNTech, Moderna and Johnson & Johnson. These companies have received use authorization from regulatory agencies in various countries, including the United States and most countries in the European Union. Each vaccine uses different technology to trigger an immune response against the virus.

How much money did the U.S. invest in COVID vaccine?

To date, the government of the United States has invested more than $30 billion in a COVID-19 vaccine. This total cost includes research, development, trials and vaccine distribution.  

What does Novavax make?

Novavax is a biotechnology company that develops vaccines for infectious diseases. It is best known for its COVID-19 vaccine, which uses a protein-based technology to trigger an immune response. In addition to a COVID-19 vaccine, Novavax is also developing vaccines for other infectious diseases, including influenza and Ebola.

My Account -